<?xml version="1.0"?>

<!DOCTYPE owl [
  <!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#">
  <!ENTITY xsd "http://www.w3.org/2001/XMLSchema#">
  <!ENTITY owl "http://www.w3.org/2002/07/owl#">
  <!ENTITY cc "http://web.resource.org/cc/#">
  <!ENTITY project "http://ebiquity.umbc.edu/ontology/project.owl#">
  <!ENTITY person "http://ebiquity.umbc.edu/ontology/person.owl#">
  <!ENTITY pub "http://ebiquity.umbc.edu/ontology/publication.owl#">
  <!ENTITY assert "http://ebiquity.umbc.edu/ontology/assertion.owl#">]>

<!--
  This ontology document is licensed under the Creative Commons
  Attribution License. To view a copy of this license, visit
  http://creativecommons.org/licenses/by/2.0/ or send a letter to
  Creative Commons, 559 Nathan Abbott Way, Stanford, California
  94305, USA.
-->

<rdf:RDF 
  xmlns:rdf = "&rdf;"
  xmlns:rdfs = "&rdfs;"
  xmlns:xsd = "&xsd;"
  xmlns:owl = "&owl;"
  xmlns:cc = "&cc;"
  xmlns:project = "&project;"
  xmlns:person = "&person;"
  xmlns:pub = "&pub;"
  xmlns:assert = "&assert;">
  <pub:Article rdf:about="http://ebiquity.umbc.edu/paper/html/id/419/Generalization-of-a-Prototype-Intelligent-Hybrid-System-for-Hard-Gelatin-Capsule-Formulation-Development">
    <rdfs:label><![CDATA[Generalization of a Prototype Intelligent Hybrid System for Hard Gelatin Capsule Formulation Development]]></rdfs:label>
    <pub:title><![CDATA[Generalization of a Prototype Intelligent Hybrid System for Hard Gelatin Capsule Formulation Development]]></pub:title>
    <pub:publishedOn rdf:datatype="&xsd;dateTime">2005-10-22T00:00:00-05:00</pub:publishedOn>
    <pub:abstract><![CDATA[The aim of this project was to expand a previously developed prototype expert network for use in the analysis of multiple biopharmaceutics classification system (BCS) class II drugs. The model drugs used were carbamazepine, chlorpropamide, diazepam, ibuprofen, ketoprofen, naproxen, and piroxicam. Recommended formulations were manufactured and tested for dissolution performance. A comprehensive training data set for the model drugs was developed and used to retrain the artificial neural network. The training and the system were validated based on the comparison of predicted and observed performance of the recommended formulations. The initial test of the system resulted in high error values, indicating poor prediction capabilities for drugs other than piroxicam. A new data set, containing 182 batches, was used for retraining. Ten percent of the test batches were used for cross-validation, resulting in models with R2 ≥ 70%. The comparison of observed performance to the predicted performance found that the system predicted successfully. The hybrid network was generally able to predict the amount of drug dissolved within 5% for the model drugs. Through validation, the system was proven to be capable of designing formulations that met specific drug performance criteria. By including parameters to address wettability and the intrinsic dissolution characteristics of the drugs, the hybrid system was shown to be suitable for analysis of multiple BCS class II drugs.]]></pub:abstract>
    <pub:number><![CDATA[3]]></pub:number>
    <pub:volume><![CDATA[6]]></pub:volume>
    <pub:counter>231</pub:counter>
    <pub:journal><![CDATA[AAPS PharmSciTech]]></pub:journal>
    <pub:publisher><![CDATA[Springer]]></pub:publisher>
    <pub:author>
       <rdf:List>
         <rdf:first><person:Collaborator rdf:about="http://ebiquity.umbc.edu/person/html/Wendy/Wilson/"><person:name><![CDATA[Wendy  Wilson]]></person:name><rdfs:label><![CDATA[Wendy  Wilson]]></rdfs:label></person:Collaborator></rdf:first>
         <rdf:rest>
           <rdf:List>
             <rdf:first><person:PrincipalFaculty rdf:about="http://ebiquity.umbc.edu/person/html/Yun/Peng/"><person:name><![CDATA[Yun  Peng]]></person:name><rdfs:label><![CDATA[Yun  Peng]]></rdfs:label></person:PrincipalFaculty></rdf:first>
             <rdf:rest>
               <rdf:List>
                 <rdf:first><person:Collaborator rdf:about="http://ebiquity.umbc.edu/person/html/Larry/L/Augsburger/"><person:name><![CDATA[Larry L Augsburger]]></person:name><rdfs:label><![CDATA[Larry L Augsburger]]></rdfs:label></person:Collaborator></rdf:first>
                 <rdf:rest rdf:resource="&rdf;nil" />
               </rdf:List>
             </rdf:rest>
           </rdf:List>
         </rdf:rest>
       </rdf:List>
    </pub:author>
    <pub:firstAuthor><person:Collaborator rdf:about="http://ebiquity.umbc.edu/person/html/Wendy/Wilson/"><person:name><![CDATA[Wendy  Wilson]]></person:name><rdfs:label><![CDATA[Wendy  Wilson]]></rdfs:label></person:Collaborator></pub:firstAuthor>
    <pub:softCopy><pub:SoftCopy>
      <pub:softCopyFormat><![CDATA[PDF Document]]></pub:softCopyFormat>
      <pub:softCopyURI><![CDATA[http://ebiquity.umbc.edu/get/a/publication/423.pdf]]></pub:softCopyURI>
      <pub:softCopySize>134000</pub:softCopySize>
    </pub:SoftCopy></pub:softCopy>
  </pub:Article>

  <rdf:Description rdf:about="">
    <cc:License rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
  </rdf:Description>

</rdf:RDF>
